AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00532701
Drug: Peg-IFN + WB RBV for 48 weeks
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 1-4~2. Rapid virologic response (RVR) at week 4 of therapy: not achieved~3. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day from weeks 5-48
Trial: NCT00532701
Drug: Peg-IFN + LD RBV for 24 weeks
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 800 mg/day from weeks 1-24~2. Rapid virologic response (RVR) at week 4 of therapy: both achieved and not achieved
Trial: NCT02365181
Drug: Ropivacaine 2 %
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 ml of Ropivacaine 2 %
Trial: NCT02041299
Drug: Deferiprone
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02041299
Drug: Deferoxamine
RxNorm normalized name: Deferoxamine
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01559545
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate release metronidazole 500 mg orally three times a day for 14 days
Trial: NCT01559545
Drug: Metronidazole-DRF1
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Modified release metronidazole (DRF1) 500 mg orally three times a day for 14 days.
Trial: NCT01559545
Drug: Metronidazole-DRF2
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Modified release metronidazole (DRF2) 500 mg orally three times a day for 14 days.
Trial: NCT01603173
Drug: Quetiapine Fumarate Tablets 25 mg
RxNorm normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg tablet once a day
Trial: NCT01603173
Drug: Quetiapine Fumarate
RxNorm normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg tablet once a day
Trial: NCT00270127
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03103646
Drug: Lu AF35700
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral use, single dose in a fasted state. EMs: 10 mg/day, PMs: 5 mg
Trial: NCT03103646
Drug: Itraconazole (200 mg)
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg Capsules for oral use, 200 mg/day. In a fed state
Trial: NCT03103646
Drug: Itraconazole (300 mg)
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg Capsules for oral use, 300 mg/day. In a fasted state.
Trial: NCT04003844
Drug: Immunoglobulin G
RxNorm normalized name: immunoglobulin G
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of IGIV 10% (2 g/kg) administered intravenously for at least 12 hours
Trial: NCT00400855
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Study drug
Trial: NCT01930604
Drug: Botox (onabotulinumtoxinA)
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Trial: NCT01930604
Drug: NaCl (placebo)
DrugBank: Linaclotide (DB08890)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006695
Drug: carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg/m2 IV on Day -6
Trial: NCT00006695
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg/m2 BID on Days -5 through -2
Trial: NCT00006695
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg/m2 BID on Days -5 through -2
Trial: NCT00006695
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 140 mg/m2 IV on Day -1
Trial: NCT00889850
Drug: 40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)
RxNorm normalized name: esomeprazole 40 MG
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg esomeprazole, single dose administration under fasted and fed condition
Trial: NCT00889850
Drug: INexium 40 mg MUPS tablets (AstraZeneca, France)
RxNorm normalized name: esomeprazole 40 MG [Nexium]
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg esomeprazole, oral single dose administration under fasted and fed condition
Trial: NCT04475107
Drug: Pyronaridine-Artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pyramax
Trial: NCT04068948
Drug: Meperidine
RxNorm normalized name: Meperidine
DrugBank: Meperidine (DB00454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This intervention assesses a child's behavioral outcome for dental procedural sedation in combination with midazolam and hydroxyzine. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
Trial: NCT04068948
Drug: Hydroxyzine
RxNorm normalized name: Hydroxyzine
DrugBank: Hydroxyzine (DB00557)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This intervention is given to children for a sedative effect. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
Trial: NCT04068948
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This intervention is given to children for a sedative effect. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
Trial: NCT01963767
Drug: NT-020
RxNorm normalized name: NT-219
DrugBank: NT-219 (DB17490)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended intake of NT-020 (NutraStem®) is two (2) capsules daily. This comprises Vitamin D3 (2000 IU), BioVin® (40 mg) and the proprietary blend (900mg). This recommended intake was calculated from doses analyzed in scientific research and based on the dose within the submitted patent.~Scientific description of the ingredients of the product per a 2 capsule dose Vitamin D3 (as cholecalciferol) - 2000 IU BioVin® Grape Extract - 40 mg Proprietary Blend - 900mg Green Tea Extract (Camellia sinensis) Wild Blueberries\* (whole fruit) Carnosine VitaBlue® Wild Blueberry Extract\*~* Vaccinium angustifolium~Other Ingredients:~Magnesium stearate, Cellulose (vegetarian capsules) Contains no yeast, wheat, corn, milk, egg, soy, glutens, artificial colors or flavors, added sugar, starch or preservatives.
Trial: NCT04451200
Drug: Busulfan Injection
RxNorm normalized name: busulfan Injection
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: injections doses will be personalized by PK at days -7 and -4
Trial: NCT04277624
Drug: fezolinetant - test formulation
RxNorm normalized name: Fezolinetant
DrugBank: Fezolinetant (DB15669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT04277624
Drug: fezolinetant - reference formulation
RxNorm normalized name: Fezolinetant
DrugBank: Fezolinetant (DB15669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03110029
Drug: Efinaconazole 10% Topical Application Solution [JUBLIA]
RxNorm normalized name: Efinaconazole 10% Topical application Solution [JUBLIA]
DrugBank: Efinaconazole (DB09040)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical efinaconazole 10% solution (Jublia)
Trial: NCT02904369
Drug: Emtricitabine
RxNorm normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02904369
Drug: Tenofovir alafenamide
RxNorm normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02904369
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00674453
Drug: Lasofoxifene
RxNorm normalized name: lasofoxifene
DrugBank: Lasofoxifene (DB06202)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Oral tablet, 0.25 mg, daily, 2 years
Trial: NCT02160158
Drug: Fesoterodine ER (fasted)
RxNorm normalized name: fesoterodine Extended Release Oral Tablet
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial Fesoterodine ER 4 mg (single dose)
Trial: NCT02160158
Drug: Fesoterodine SR3 (fasted)
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fesoterodine SR3 4 mg (single dose)
Trial: NCT02160158
Drug: Fesoterodine SR3 (fed)
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fesoterodine SR3 4 mg (single dose) with high-fat meal
Trial: NCT00532129
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375mg/m\^2 IV on Day 1 of Cycle 1; 500mg/m\^2 on Day 1 of Cycles 2-6.
Trial: NCT00532129
Drug: Chlorambucil
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/m\^2/day PO on Days 1 to 7 of each cycle for a maximum of 12 cycles.
Trial: NCT02160158
Drug: Fesoterodine ER (fed)
RxNorm normalized name: fesoterodine Extended Release Oral Tablet
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial Fesoterodine ER 4 mg (single dose) with high-fat meal
Trial: NCT02160158
Drug: Fesoterodine SR3 (sprinkle)
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fesoterodine SR3 4 mg (single dose) beads sprinkled on applesauce
Trial: NCT02160158
Drug: Fesoterodine SR4 (fasted)
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fesoterodine SR4 4 mg (single dose)
Trial: NCT02160158
Drug: Fesoterodine SR4 (fed)
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fesoterodine SR4 4 mg (single dose) with high-fat/high calorie meal
Trial: NCT02160158
Drug: Fesoterodine SR4 (sprinkle)
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fesoterodine SR4 4 mg (single dose) beads sprinkled on applesauce
Trial: NCT02386462
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The modified Dixon's up-and-down method was used to determine the bolus dose of dexmedetomidine, starting from 1.0μg/kg (step size; 0.1μg/kg)
Trial: NCT02386462
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04051047
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants receive a one time IV dose of gemcitabine prior to having standard of care surgery.
Trial: NCT00335972
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine, 0.5-1 µg/kg, will be infused over 20 minutes, immediately followed by an infusion at a rate of 0.2 µg/kg/hr until the end of surgery (For patients in renal failure, the loading dose will be 0.2 µg/kg). The infusion rate will be reduced as necessary to maintain acceptable blood pressure and heart rate. Propofol will be titrated to maintain BIS as close to 45 as clinically practical.
Trial: NCT06473259
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 courses of docetaxel 75 mg/sqm iv
Trial: NCT06473259
Drug: Apalutamide Oral Tablet
RxNorm normalized name: apalutamide Oral Tablet
DrugBank: Apalutamide (DB11901)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 240 mg /daily orally
Trial: NCT06473259
Drug: Enzalutamide Oral Tablet
RxNorm normalized name: enzalutamide Oral Tablet
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg /daily orally
Trial: NCT06473259
Drug: Abiraterone acetate tablets
RxNorm normalized name: Abiraterone Acetate Tablets
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg /daily orally
Trial: NCT06473259
Drug: Darolutamide Oral Tablet
RxNorm normalized name: darolutamide Oral Tablet
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 600 mg/daily orally
Trial: NCT06473259
Drug: Triptorelin
RxNorm normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3,75 mg im/4 w
Trial: NCT01741181
Drug: Vitamin D supplementation
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 marketed by oneNine57
Trial: NCT02603679
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Any brand of paclitaxel may be used, excluding nab-paclitaxel
Trial: NCT02603679
Drug: Tamoxifen + Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Any brand of tamoxifen may be used
Trial: NCT02603679
Drug: Aromatase Inhibitor + Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Any brand of letrozole, anastrozole or exemestane may be used
Trial: NCT02603679
Drug: Goserelin + Aromatase Inhibitor + Palbociclib
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Any brand of letrozole, anastrozole or exemestane may be used
Trial: NCT01741493
Drug: Tofacitinib
RxNorm normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral administration
Trial: NCT01396187
Drug: PF-05231023
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg IV twice a week for 4 weeks
Trial: NCT01396187
Drug: PF-05231023
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg IV twice a week for 4 weeks
Trial: NCT01396187
Drug: PF-05231023
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg IV twice a week for 4 weeks
Trial: NCT01396187
Drug: PF-05231023
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg IV twice a week for 4 weeks
Trial: NCT01504295
Drug: Metadoxine
RxNorm normalized name: metadoxine
DrugBank: Metadoxine (DB16554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improve Liver Function and Reduce ALcohol Use
Trial: NCT02469454
Drug: early insertion
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 48 h postpartum.
Trial: NCT01674504
Drug: Montelukast sodium chewable tablets 4 mg and 5 mg
RxNorm normalized name: montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast sodium chewable tablets 4mg and 5mg
Trial: NCT00756275
Drug: Nicotine Replacement Treatment (NRT)
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement treatment (NRT) will follow the clinical practice guidelines for nicotine patch for people smoking at least 10 cigarettes per day (USDHHS, 2000), modified to allow 12 weeks use (tapering recommended for people with AUDs by Hughes et al., 2003b): 21 mg/day for 4 weeks, 14 mg/day for 4 weeks, 7 mg/day for 4 weeks.
Trial: NCT00756275
Drug: varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Varenicline (VAR, 2 mg/d in divided doses) will be administered as follows. VAR: participant takes 0.5 mg/d for the first 3 days, 1 mg/d (0.5 mg 2x/d) for the next 4 days, and 2mg/d (1.0mg 2x/d) for 12 weeks.
Trial: NCT01721382
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00310531
Drug: Menostar (Estradiol, BAY86-5435)
RxNorm normalized name: Menostar
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Menostar (estradiol transdermal delivery system (SHP00577E), 0.014 mg/day)
Trial: NCT00310531
Drug: Raloxifene
RxNorm normalized name: Raloxifene
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raloxifene tbl. (60 mg/day)
Trial: NCT02484963
Drug: Zolpidem
RxNorm normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00622479
Drug: Sorafenib (Nexavar, BAY43-9006)
RxNorm normalized name: sorafenib 200 MG [Nexavar]
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib will be administered at 400mg BID for a 28 day cycle.
Trial: NCT04477811
Drug: Vitamin K1
RxNorm normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vitamin k1 tablets
Trial: NCT04477811
Drug: Vitamin k2
RxNorm normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vitamin k2 45 ug tablets twice daily
Trial: NCT02802592
Drug: Epogen
RxNorm normalized name: Epogen
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm
Trial: NCT01547000
Drug: extended-release guanfacine (Intuniv)
RxNorm normalized name: guanfacine Extended Release Oral Tablet
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks.
Trial: NCT02257242
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m2 I.V. on Day 1 of each cycle
Trial: NCT02257242
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 90 mg/m2 I.V. on Day 1 and 2 of each cycle
Trial: NCT02257242
Drug: Vincristine sulfate liposome injection
RxNorm normalized name: Vincristine Sulfate Liposome Injection
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose per dose escalation protocol, I.V. on Day 2 of each cycle
Trial: NCT00276406
Drug: Pyridostigmine
RxNorm normalized name: Pyridostigmine
DrugBank: Pyridostigmine (DB00545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyridostigmine will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.
Trial: NCT00988156
Drug: Eslicarbazepine acetate (BIA 2-093)
RxNorm normalized name: Eslicarbazepine
DrugBank: Eslicarbazepine acetate (DB09119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part I - 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.~The recommended target dose of double-blind study treatment will be 20mg/kg/day.~Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year.
Trial: NCT00988156
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine acetate (DB09119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part I: 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.~Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year.
Trial: NCT01303952
Drug: Eculizumab
RxNorm normalized name: Eculizumab
DrugBank: Eculizumab (DB01257)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly treatment with eculizumab (600 mg) via IV infusion for 4 doses followed the next week by eculizumab (900 mg) IV infusion and maintenance treatment with Eculizumab (900 mg) via IV infusion every other week for 21 weeks
Trial: NCT03909412
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carfilzomib will be administered over 10 minutes for the 20 mg/m2 and 27 mg/m2 dose and over 30 minutes for all higher doses.
Trial: NCT03909412
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 40mg IV/PO to be administered as a premedication.
Trial: NCT03909412
Drug: Granulocyte Colony-Stimulating Factor
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: On day 7 subjects will initiate high dose G-CSF injections at 14mcg/kg daily (with a cap of 1440mcg daily).
Trial: NCT02882854
Drug: Guanfacine
RxNorm normalized name: Guanfacine
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive 1 mg of guanfacine to take orally.